Alembic Straddles Oversupply And Shortages In US

One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.